Man Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.8M | Buy |
415,909
+184,699
| +80% | +$24.5M | 0.1% | 224 |
|
|
2025
Q4 | $32.8M | Buy |
231,210
+150,378
| +186% | +$21.8M | 0.06% | 332 |
|
|
2025
Q3 | $11.3M | Buy |
80,832
+33,606
| +71% | +$4.55M | 0.02% | 730 |
|
|
2025
Q2 | $5.94M | Sell |
47,226
-52,962
| -53% | -$6.07M | 0.01% | 985 |
|
|
2025
Q1 | $11.1M | Sell |
100,188
-44,976
| -31% | -$5.7M | 0.03% | 688 |
|
|
2024
Q4 | $19.8M | Sell |
145,164
-151,015
| -51% | -$18.7M | 0.05% | 430 |
|
|
2024
Q3 | $34.1M | Buy |
296,179
+62,954
| +27% | +$8.63M | 0.09% | 278 |
|
|
2024
Q2 | $32.1M | Sell |
233,225
-56,536
| -20% | -$7.75M | 0.08% | 274 |
|
|
2024
Q1 | $40M | Sell |
289,761
-28,673
| -9% | -$3.92M | 0.1% | 223 |
|
|
2023
Q4 | $42M | Buy |
+318,434
| New | +$36.7M | 0.12% | 206 |
|
|
2023
Q3 | – | Sell |
-630,747
| Closed | -$66.4M | – | 199 |
|
|
2023
Q2 | $59.5M | Buy |
+630,747
| New | +$61.6M | 0.18% | 122 |
|
|
2023
Q1 | – | Sell |
-315,970
| Closed | -$32.9M | – | 93 |
|
|
2022
Q4 | $37.7M | Buy |
315,970
+210,283
| +199% | +$24.6M | 0.14% | 187 |
|
|
2022
Q3 | $11.2M | Buy |
+105,687
| New | +$10.7M | 0.05% | 437 |
|
|
2022
Q2 | – | Sell |
-247,313
| Closed | -$22.8M | – | 1013 |
|
|
2022
Q1 | $23.2M | Buy |
247,313
+13,750
| +6% | +$1.17M | 0.08% | 279 |
|
|
2021
Q4 | $19.9M | Buy |
+233,563
| New | +$21.5M | 0.06% | 373 |
|
|
2021
Q1 | – | Sell |
-2,107
| Closed | -$202K | – | 1950 |
|
|
2020
Q4 | $202K | Sell |
2,107
-186,516
| -99% | -$18M | ﹤0.01% | 1737 |
|
|
2020
Q3 | $18.1M | Buy |
188,623
+93,819
| +99% | +$10.9M | 0.07% | 296 |
|
|
2020
Q2 | $11.6M | Buy |
94,804
+47,147
| +99% | +$5.21M | 0.06% | 314 |
|
|
2020
Q1 | $4.12M | Buy |
47,657
+35,019
| +277% | +$3.43M | 0.03% | 566 |
|
|
2019
Q4 | $1.36M | Buy |
12,638
+5,099
| +68% | +$534K | ﹤0.01% | 1428 |
|
|
2019
Q3 | $679K | Sell |
7,539
-48,564
| -87% | -$4.54M | ﹤0.01% | 1515 |
|
|
2019
Q2 | $4.74M | Sell |
56,103
-30,075
| -35% | -$2.47M | 0.02% | 970 |
|
|
2019
Q1 | $7.59M | Sell |
86,178
-69,706
| -45% | -$5.83M | 0.03% | 701 |
|
|
2018
Q4 | $11.1M | Buy |
155,884
+141,180
| +960% | +$13.5M | 0.05% | 424 |
|
|
2018
Q3 | $1.81M | Sell |
14,704
-2,620
| -15% | -$297K | 0.01% | 1460 |
|
|
2018
Q2 | $1.7M | Sell |
17,324
-5,125
| -23% | -$459K | 0.01% | 1421 |
|
|
2018
Q1 | $1.86M | Buy |
+22,449
| New | +$1.9M | 0.01% | 1311 |
|
Other funds holding NBIX
VPM
VCM
Man Group's NBIX Position: Q1 2026 in Review
Man Group increased its Neurocrine Biosciences (NBIX) stake by 80% in Q1 2026, buying an estimated $24.5M and bringing the position to 415,909 shares worth $54.8M. The position accounts for 0.1% of the portfolio, ranked #224.
Man Group first reported a position in NBIX in Q1 2018 and has held it in 27 quarters since. The position peaked at $59.5M in Q2 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Man Group held 415,909 shares of Neurocrine Biosciences worth $54.8M as of Q1 2026.
- Man Group bought 184,699 Neurocrine Biosciences shares in Q1 2026, an estimated $24.5M.
- Neurocrine Biosciences made up 0.1% of Man Group's portfolio in Q1 2026, its #224 holding.
- Man Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 27 quarters since.
- Man Group's Neurocrine Biosciences position peaked at $59.5M in Q2 2023.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.